Boston Life Sciences, Inc. Announces Appointment of Chief Medical Officer

"Mark brings a wealth of knowledge, experience and energy toBoston Life Sciences. He has been involved with the clinical andregulatory approval programs of CNS products in the pharmaceuticalindustry for many years," said Dr. Mark Pykett, President and COO ofBLSI. "His depth of experience in drug development should addimmediate value to our late-stage molecular imaging program forALTROPANE in Parkinson's disease and ADHD and should accelerate theprogress of our stroke and Parkinson's Disease therapy programs. Underhis direction, we expect Mark will help guide the efficient, focusedclinical development plans for our pre-clinical candidates and assistin the evaluation of new CNS pipeline opportunities."

Most recently, Dr. Hurtt was Senior Director of Clinical Researchat Neurogen Corporation (Branford, CT). Prior to Neurogen, Mark wasDirector of Drug Development and Director of Clinical Research atPfizer Global Research and Development in Ann Arbor, MI. During hiscareer, Dr. Hurtt has overseen CNS development programs in Parkinson'sDisease, Alzheimer's disease, schizophrenia, pain, anxiety anddepression. Dr. Hurtt is Board certified in Neurology andNeuropathology. He received his medical degree from Jefferson MedicalCollege and served as a Medical Officer in the United States Navy. Hetrained in neurology and neuropathology and was an assistant professorin the Departments of Neurology and Pathology at the University ofPittsburgh.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research andclinical development of diagnostic and therapeutic products forcentral nervous system (CNS) disorders. ALTROPANE(R) molecular imagingagent is in Phase III clinical trials for the diagnosis ofParkinsonian Syndrome (PS) and a Phase II clinical trial for thediagnosis of Attention Deficit Hyperactivity Disorder (ADHD). TheCompany's research and pre-clinical CNS programs include Inosine forthe treatment of stroke, O-1369 for the treatment of Parkinson'sdisease and FLUORATEC(TM), a second generation molecular imagingagent, for PS and ADHD. BLSI's current research collaborations includeHarvard Medical School, Children's Hospital of Boston and theUniversity of Massachusetts-Worcester.

ALTROPANE is a registered trademark of Boston Life Sciences, Inc.

The foregoing release contains certain forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of1995. Forward-looking statements include statements regarding BostonLife Sciences' expectations, beliefs, intentions or strategiesregarding the future, including the Company's development effortsregarding the Company's ALTROPANE program and the Company'spre-clinical candidates. Forward-looking statements can be identifiedby terminology such as "anticipate," "believe," "could," "couldincrease the likelihood," "estimate," "expect," "intend," "isplanned," "may," "should," "will," "will enable," "would be expected,""look forward," "may provide," "would" or similar terms, variations ofsuch terms or the negative of those terms. Such forward-lookingstatements involve known and unknown risks, uncertainties and otherfactors including those risks, uncertainties and factors referred toin the Company's Quarterly Report on form 10-Q for the quarter endedJune 30, 2005, filed with the Securities and Exchange Commission underthe section "Risk Factors," as well as other documents that may befiled by Boston Life Sciences from time to time with the Securitiesand Exchange Commission. As a result of such risks, uncertainties andfactors, the Company's actual results may differ materially from anyfuture results, performance or achievements discussed in or implied bythe forward-looking statements contained herein. Boston Life Sciences,Inc. is providing the information in this press release as of thisdate and does not undertake any obligation to update anyforward-looking statements contained in this press release as a resultof new information, future events or otherwise.